In cancer-bearing animals or patients, Tregs expand, migrate to tumor sites, and suppress antitumor immune response mediated by NK cells, CD4+ and CD8+ T cells, and myeloid cells, through different molecular mechanisms [97]. This evidence concerns the gene CD4 and neoplasm.